Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Gw 780604
2. Gw 786034b
3. Gw-780604
4. Gw-786034b
5. Gw780604
6. Gw786034b
7. Pazopanib
8. Votrient
1. 635702-64-6
2. Pazopanib Hcl
3. Votrient
4. Pazopanib (hydrochloride)
5. Armala
6. Unii-33y9anm545
7. Pazopanib Monohydrochloride
8. Pazopanib Hcl (gw786034 Hcl)
9. Gw786034b
10. Gw-786034b
11. Pazopanib (as Hydrochloride)
12. Gw786034 (hydrochloride)
13. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
14. Chebi:71217
15. 33y9anm545
16. S1035
17. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Hydrochloride
18. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Monohydrochloride
19. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide Hydrochloride
20. 5-{4-[(2,3-dimethyl-2h-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide Hydrochloride
21. Benzenesulfonamide, 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, Monohydrochloride
22. Patorma
23. Gw786034 Hcl
24. Votrient Hcl
25. Votrient (tn)
26. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide Hydrochloride
27. Pazopanib Hydrochloride [usan:jan]
28. Mls004774147
29. Schembl159487
30. Pazopanib Hydrochloride- Bio-x
31. Pazopanib Hydrochloride [usan]
32. Chembl1201733
33. Dtxsid70212956
34. Ex-a956
35. Pazopanib Hcl (gw786034 )
36. Bcp02203
37. Pazopanib Hydrochloride (jan/usan)
38. Pazopanib Hydrochloride [mi]
39. Mfcd12546138
40. Nsc737754
41. Pazopanib Hydrochloride [jan]
42. Akos015958593
43. Bcp9001052
44. Ccg-269485
45. Cs-0126
46. Gsk-786034
47. Ks-1458
48. Nsc-737754
49. Pazopanib Hydrochloride [mart.]
50. Pb31655
51. Sb10367
52. Pazopanib Hydrochloride [who-dd]
53. Ac-24726
54. Bp166746
55. Hy-12009
56. Smr003500790
57. Am20090655
58. Ft-0687642
59. P2243
60. Pazopanib Hydrochloride [orange Book]
61. Sw218082-2
62. Ec-000.2347
63. D05380
64. A834417
65. Q27888072
66. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride
67. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride
68. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride;5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide Hydrochloride
69. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
70. Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, Hydrochloride (1:1)
Molecular Weight | 474.0 g/mol |
---|---|
Molecular Formula | C21H24ClN7O2S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 473.1400719 g/mol |
Monoisotopic Mass | 473.1400719 g/mol |
Topological Polar Surface Area | 127 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 717 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Votrient |
PubMed Health | Pazopanib (By mouth) |
Drug Classes | Antineoplastic Agent, Immunological Agent |
Active Ingredient | Pazopanib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base; eq 400mg base |
Market Status | Prescription |
Company | Glaxosmithkline |
2 of 2 | |
---|---|
Drug Name | Votrient |
PubMed Health | Pazopanib (By mouth) |
Drug Classes | Antineoplastic Agent, Immunological Agent |
Active Ingredient | Pazopanib hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base; eq 400mg base |
Market Status | Prescription |
Company | Glaxosmithkline |
* Renal-cell carcinoma (RCC):
Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
* Soft-tissue sarcoma (STS):
Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.
Efficacy and safety have only been established in certain STS histological tumour subtypes.
L01XE11
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ANALYTICAL
ABOUT THIS PAGE
A Pazopanib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pazopanib, including repackagers and relabelers. The FDA regulates Pazopanib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pazopanib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pazopanib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pazopanib supplier is an individual or a company that provides Pazopanib active pharmaceutical ingredient (API) or Pazopanib finished formulations upon request. The Pazopanib suppliers may include Pazopanib API manufacturers, exporters, distributors and traders.
click here to find a list of Pazopanib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pazopanib DMF (Drug Master File) is a document detailing the whole manufacturing process of Pazopanib active pharmaceutical ingredient (API) in detail. Different forms of Pazopanib DMFs exist exist since differing nations have different regulations, such as Pazopanib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pazopanib DMF submitted to regulatory agencies in the US is known as a USDMF. Pazopanib USDMF includes data on Pazopanib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pazopanib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pazopanib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pazopanib Drug Master File in Korea (Pazopanib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pazopanib. The MFDS reviews the Pazopanib KDMF as part of the drug registration process and uses the information provided in the Pazopanib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pazopanib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pazopanib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pazopanib suppliers with KDMF on PharmaCompass.
A Pazopanib written confirmation (Pazopanib WC) is an official document issued by a regulatory agency to a Pazopanib manufacturer, verifying that the manufacturing facility of a Pazopanib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pazopanib APIs or Pazopanib finished pharmaceutical products to another nation, regulatory agencies frequently require a Pazopanib WC (written confirmation) as part of the regulatory process.
click here to find a list of Pazopanib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pazopanib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pazopanib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pazopanib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pazopanib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pazopanib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pazopanib suppliers with NDC on PharmaCompass.
Pazopanib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pazopanib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pazopanib GMP manufacturer or Pazopanib GMP API supplier for your needs.
A Pazopanib CoA (Certificate of Analysis) is a formal document that attests to Pazopanib's compliance with Pazopanib specifications and serves as a tool for batch-level quality control.
Pazopanib CoA mostly includes findings from lab analyses of a specific batch. For each Pazopanib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pazopanib may be tested according to a variety of international standards, such as European Pharmacopoeia (Pazopanib EP), Pazopanib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pazopanib USP).
LOOKING FOR A SUPPLIER?